Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction

(2011) Takara L Stanley et al.   AIDS

Endothelial function is impaired in HIV-infected patients with lipodystrophy

(2010) Mar Masiá et al.   ANTIVIRAL THERAPY

Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension

(2010) Julian Falutz et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data

(2010) Julian Falutz et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects

(2009) Giovanni Guaraldi et al.   ATHEROSCLEROSIS

Impact of Growth Hormone Receptor Blockade on Substrate Metabolism during Fasting in Healthy Subjects

(2009) Louise Moller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

(2008) Julian Falutz et al.   AIDS

Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006

(2008) A Nguyen et al.   HIV MEDICINE

The Associations of Regional Adipose Tissue With Lipid and Lipoprotein Levels in HIV-Infected Men

(2008) David Wohl et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Low-Dose Physiological Growth Hormone in Patients With HIV and Abdominal Fat Accumulation

(2008) Janet Lo   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION